Abstract
Ganoderma lucidum (Lingzhi) polysaccharide peptide (GL-pp) is a bioactive component of a globally recognized traditional Chinese medicine, known for its sedative, hypnotic, and immune-regulatory properties. This study investigates the impact of sleep fragmentation (SF) on melanoma metastasis and evaluates the therapeutic potential of GL-pp. Using a B16-F10-luc-G5 melanoma mouse model, researchers demonstrated that SF significantly facilitates tumor metastasis. Conversely, oral administration of GL-pp at 80 mg/kg significantly reduced metastatic burden. Through a multi-omics approach, the study revealed that GL-pp modulates the lung proteome, restores gut microbiota balance, and shifts the immune environment from pro-tumor to anti-tumor.
Introduction
Chronic sleep fragmentation (SF) is a hallmark of modern lifestyle and sleep apnea, increasingly linked to the progression of various diseases, including cancer. While previous experimental studies have shown that SF can promote primary tumor development, its specific influence on metastasis—the spread of cancer to distant organs—remains an area of active investigation. This research explores the antimetastatic effects of Ganoderma lucidum polysaccharide peptide (GL-pp), a derivative of the 'mushroom of immortality,' in a mouse model of melanoma subjected to chronic sleep disruption.
Methods
The researchers employed BALB/c nude mice injected with luciferase-tagged B16-F10-luc-G5 melanoma cells to track metastasis in real-time. Sleep fragmentation was induced using an automated sweeping pole system that interrupted the mice's sleep cycles between 12 a.m. and 4 p.m. daily.
The study compared three primary groups: a normal sleep tumor group, an SF tumor group (T+SF), and an SF tumor group treated with 80 mg/kg of GL-pp. The researchers utilized a comprehensive analytical suite, including:
- Bioluminescence Imaging: To quantify metastatic spread in vivo.
- Quantitative Proteomics: Using LC-MS/MS to analyze protein expression changes in lung tissue.
- 16S rRNA Sequencing: To evaluate changes in the gut microbiome composition.
- Immune Profiling: Measuring macrophage polarization (M1 vs. M2) and serum TNF-α levels via flow cytometry and ELISA.
Datasets
Proteomic data was submitted to the UniProt human protein database and the ProteomeXchange Consortium (Identifier: PXD025171). Microbiota sequencing data (16S rRNA) is available via the NCBI SRA database (Accession: PRJNA680896).
Results and Discussion
Inhibition of SF-Induced Metastasis
The study confirmed that sleep fragmentation acts as a potent catalyst for cancer progression, significantly increasing the number of metastatic foci in the lungs. However, GL-pp treatment effectively mitigated this acceleration. Bioluminescence imaging revealed that mice receiving GL-pp had significantly lower luminescent intensity and fewer metastatic colonies compared to the SF-only group (p < 0.05).
Proteomic Rewiring and the Gut-Lung Axis
Proteomic analysis of lung tissue identified 227 proteins that were differentially expressed following GL-pp treatment. Functional clustering pointed toward 'focal adhesion' and 'response to hormone' as key pathways modulated by the treatment. Notably, GL-pp upregulated Lama2 (Laminin alpha 2), a protein often associated with tumor suppression.
Furthermore, the study highlighted a clear 'gut-lung axis' connection. SF disrupted the gut microbiome, notably increasing the Firmicutes-to-Bacteroidetes ratio—a common marker of dysbiosis. GL-pp administration reversed these microbial shifts, suggesting that its antimetastatic effects may be partially mediated by the restoration of gut health.
Immune Reprogramming and Inflammation
Tumors often manipulate the immune system by recruiting macrophages and polarizing them into a pro-tumor M2 phenotype. The researchers found that SF exacerbated this trend, but GL-pp treatment successfully shifted the balance back toward the anti-tumor M1 phenotype. Additionally, GL-pp significantly reduced systemic inflammation, as evidenced by a marked decrease in serum TNF-α levels, which were otherwise elevated by sleep fragmentation.
Conclusion
This study provides compelling evidence that GL-pp can counteract the metastatic promotion caused by sleep fragmentation. By integrating proteomic, microbiomic, and immunologic data, the researchers have mapped a multi-faceted mechanism of action for this traditional medicine derivative. While the study's use of nude mice limits findings regarding the adaptive immune response, the results offer a promising foundation for future clinical research into using GL-pp as a supportive therapy for cancer patients with sleep disorders.
Summary updated